Novo Nordisk Continues to Limit Supply of Blockbuster Weight-Loss Drug

Novo Nordisk is gradually expanding supply capacity for its blockbuster weight-loss drug, but said it will continue to limit supply of lower-strength doses of the Wegovy medicine in the U.S. as it seeks to safeguard supplies.